Biden Gives Becerra 45 Days to Deliver a Plan to Fight Excessive Drug Prices

President Biden has given HHS Secretary Xavier Becerra an Aug. 23 deadline for a plan “to combat excessive pricing of prescription drugs.”

President Biden last Friday gave U.S. Health and Human Services Secretary Xavier Becerra 45 days to deliver a plan “to combat excessive pricing of prescription drugs.” Becerra’s deadline is Aug. 23.

Biden included drug pricing directives in a far-ranging July

Read More »

HRSA Makes Tweaks to 340B Program Database

HRSA yesterday announced changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.

The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) posted a notice yesterday about changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.

Today is the first day

Read More »

Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly

Lilly, Novartis, and Sanofi sent HRSA defiant responses to its May 17 letters telling the companies that their 340B contract pharmacy policies were illegal.
On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law. At least three of
Read More »

CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program

Massachusetts Medicaid director Daniel Tsai has been named Director of CMS’s Center for Medicaid and CHIP Services.
The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS).
Read More »

NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month

President Biden has yet to select a new leader for the Health Resources and Services Administration, the federal agency responsible for the 340B drug pricing program.

Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.

This normally might be a

Read More »

News Alert: Becerra Puts His Imprint On Long-Awaited 340B Dispute Resolution Board

HHS Secretary Xavier Becerra made appointments today to the 340B administrative dispute resolution board. | Shutterstock

U.S. Health and Human Services (HHS) Secretary Xavier Becerra early this morning announced his six appointees to the long-awaited 340B administrative dispute resolution (ADR) board.

The move will be welcomed by the 340B provider community, which has pushed for the

Read More »

BREAKING: HHS Withdraws 340B Contract Pharmacy Advisory Opinion, and Becerra Appoints 340B Dispute Resolution Board Members

HHS yesterday withdrew its ex-General Counsel Robert Charrow's legal advisory opinion that the 340B statute requires drug companies to offer 340B pricing when covered entities use contract pharmacies.
The U.S. Health and Human Services Department (HHS) yesterday withdrew its December 2020 legal advisory opinion on 340B contract pharmacy. Also, HHS Secretary Xavier Becerra appointed members to the 340B program administrative dispute resolution (ADR) board.
Read More »

Biden Administration Proposes to Rescind Trump’s 340B Health Center Insulin Rule

The Biden administration today moved to rescind the Trump administration final rule requiring health centers to pass along their 340B savings on insulin and epinephrine pens to low-income patients.
The Biden administration this morning formally announced plans to rescind the controversial Trump administration final rule requiring community health centers to pass along all 340B drug discount savings on insulin and injectable epinephrine to low-income patients, as a condition for
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 6

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
As we described in Parts 2 and 3 of this series, in 2018, an ex-Celgene vice president responsible for the company’s 340B program compliance alleged in a whistleblower lawsuit that Celgene’s reason for limiting Revlimid, Pomalyst, and Thalomid’s distribution is
Read More »
Generic selectors
Exact matches only
Search in title
Search in content